Renowned German pathologist Professor Ashraf Dada completed his secondary education in Muenster in 1987, followed by studying medicine at the University of Erlangen, where he earned his doctorate in 1995. He obtained The German Board in transfusion medicine and immunohematology from Stuttgart in 2000. From 2001 to 2007, Dr. Dada served as Senior Consultant and Chairman of the Department of Immunohematology & Transfusion Medicine at the University Hospital Regensburg, where he chaired the transfusion committee and received multiple recognitions and awards from the university for his outstanding achievements in the transfusion medicine. In 2008, he was appointed General Manager of Synlab Transfusion Institute Munich and later became President of the Synlab European Advisory Board for Transfusion Medicine and Immunohematology across 35 EU countries. A historic achievement in his career was the successful isolation of Regulatory T-Cells (CD4+/CD25+) in 2006 at the University Hospital Regensburg, pivotal for inducing immune tolerance post-transplantation and mitigating hyperactive immune responses in critically ill COVID-19 patients. Driven by a commitment to global health, Dr. Dada initiated a groundbreaking phase II clinical trial at King Faisal Specialist Hospital & Research Centre in Jeddah (KFSH&RC-J), managing critically ill COVID-19 patients with high-titer competent immune plasma from recovered volunteers. This intervention notably reduced mortality rates in ICU COVID-19patients from 30% to 5% only. His research was published in the journal Intervirology, and he was honored with the First Place Award for distinguished COVID-19 research by the Research Center of KFSH&RC-Jeddah in 2022. In 2019, he earned certification as a Director from the American Society for Histocompatibility & Immunogenetics (ASHI), one of the few in the Middle East. Consequently, in 2021, Dr. Dada's election as President of the Arabian Society for Histocompatibility and Immunogenomics (ARSHI) marked a further milestone in his career. Currently, he serves as Chairman of the Pathology and Laboratory Medicine Department, Director of the HLA-Lab, Transfusion Medicine and Blood Bank at King Faisal Specialist Hospital & Research Centre-Jeddah (KFSH&RC-J), and holds a full Professorship at the Faculty of Medicine at Al-Faisal University in Riyadh. His prolific scientific contributions are evident in numerous publications, including in the prestigious Nature Journal, with an impact factor, exceeding 200. Recently, Dr. Dada developed at KFSH&RC-J an innovative protocol for the treatment of Xanthoma that considered previously as untreatable. This innovative therapeutic protocol found a great international resonance and publicity and was published in the prestigious journal JCEM. Dr. Dada has conducted over 300 TV interviews on immunological and viral disorders, mainly COVID-19. In 2022, Dr. Dada was nominated by the administration of KFSH&RC-J for the King Faisal International Prize in Medicine for the year 2023.